Safety and efficacy of meningococcal C vaccination in juvenile idiopathic arthritis

Arthritis and Rheumatism

Volumn 56, Issue 2, 2007, Pages 639-646

  Zonneveld Huijssoon, Evelien ^a   Ronaghy, Arash ^a   Van Rossum, Marion A J ^b   Rijkers, Ger T ^a   Van Der Klis, Fiona R M ^c   Sanders, Elisabeth A M ^a   Vermeer De Bondt, Patricia E ^c   Hoes, Arno W ^a   Van Der Net, Jan Jaap ^a   Engels, Carla ^a   Kuis, Wietse ^a   Prakken, Berent J ^a   Van Tol, Maarten J D ^b   Wulffraat, Nico M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MENINGOCOCCUS VACCINE; METHOTREXATE; NEISVAC C; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; NETHERLANDS; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; SERUM BACTERICIDAL ACTIVITY; STATISTICAL ANALYSIS; VACCINATION;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; BLOOD BACTERICIDAL ACTIVITY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NETHERLANDS; RECURRENCE;

EID: 33847019527     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22399     Document Type: Article

References (59)

1. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? [review]. Lancet 2003;362:1659-66.
2. Ravel G, Christ M, Horand F, Descotes J. Autoimmunity, environmental exposure and vaccination: is there a link? Toxicology 2004;196:211-6.
3. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines [review]. Vaccine 2005;23:3876-86.
4. Gellin BG, Schaffner W. The risk of vaccination: the importance of "negative" studies. N Engl J Med 2001;344:372-3.
5. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S, for the Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001;344:319-26.
6. Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327-32.
7. Graves PM, Barriga KJ, Norris JM, Hoffman MR, Yu L, Eisenbarth GS, et al. Lack of association between early childhood immunizations and β-cell autoimmunity. Diabetes Care 1999;22:1694-7.
8. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001;19:589-94.
9. Malleson PN, Tekano JL, Scheifele DW, Weber JM. Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol 1993;20:1769-73.
10. Kasapcopur O, Cullu F, Kamburoglu-Goksel A, Cam H, Akdenizli E, Calykan S, et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1128-30.
11. Offit PA, Hackett CJ. Addressing parents' concerns: do vaccines cause allergic or autoimmune diseases? [review]. Pediatrics 2003; 111:653-9.
12. Hak E, Schonbeck Y, De Melker H, Van Essen GA, Sanders EA. Negative attitude of highly educated parents and health care workers towards future vaccinations in the Dutch childhood vaccination program. Vaccine 2005;23:3103-7.
13. Inspectorate for Dutch Health Care. Vaccination situation in the Netherlands per January 2002 [with abstract in English]. The Hague, The Netherlands; 2004.
14. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
15. Davies K, Woo P. Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence. Rheumatology (Oxford) 2002;41:937-41.
16. BSR Clinical Affairs Committee. Vaccinations in the immunocompromised person: guidelines for the patient taking immunosuppressants, steroids and the new biologic therapies. London: British Society for Rheumatology; 2002.
17. Conyn-van Spaendonck MA, Reintjes R, Spanjaard L, van Kregten E, Kraaijeveld AG, Jacobs PH. Meningococcal carriage in relation to an outbreak of invasive disease due to Neisseria meningitidis serogroup C in the Netherlands. J Infect 1999;39:42-8.
18. Van Furth AM, Vandenbroucke-Grauls CM. Universal vaccination against group C meningococci and pneumococci; advice from the Health Council of the Netherlands. Ned Tijdschr Geneeskd 2002;146:932-3.
19. World Health Organization. Causality assessment of adverse events following immunization. Wkly Epidemiol Rec 2001;76:85-9.
20. Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001;84:227-9.
21. Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ 1992;304:1075-8.
22. Abeyagunawardena AS, Goldblatt D, Andrews N, Trompeter RS. Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. Lancet 2003;362:449-50.
23. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
24. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
25. Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology. Clin Exp Rheumatol 2001;19(4 Suppl 23):S1-9.
26. Wulffraat N, van der Net JJ, Ruperto N, Kamphuis S, Prakken BJ, Ten Cate R, et al. The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19(4 Suppl 23): S111-5.
27. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
28. Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1058-64.
29. Gheesling LL, Carlone GM, Pais LB, Holder PF, Maslanka SE, Plikaytis BD, et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 1994;32:1475-82.
30. Holder PK, Maslanka SE, Pais LB, Dykes J, Plikaytis BD, Carlone GM. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992. Clin Diagn Lab Immunol 1995;2:132-7.
31. Maslanka SE, Tappero JW, Plikaytis BD, Brumberg RS, Dykes JK, Gheesling LL, et al. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect Immun 1998;66:2453-9.
32. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotshlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 1979;140:690-7.
33. Hendriksen CF, van der Gun JW, Kreeftenberg JG. Combined estimation of tetanus and diphtheria antitoxin in human sera by the in vitro toxin-binding inhibition (ToBI) test. J Biol Stand 1989;17:191-200.
34. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al, for the Multilaboratory Study Group. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997;4:156-67.
35. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001;69:1568-73.
36. Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996;174:1360-3.
37. King WJ, MacDonald NE, Wells G, Huang J, Allen U, Chan F, et al. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children. J Pediatr 1996;128:196-202.
38. Mitchell LA, Ochnio JJ, Glover C, Lee AY, Ho MK, Bell A. Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents. J Infect Dis 1996;173:1009-13.
39. Lepow ML, Beeler J, Randolph M, Samuelson JS, Hankins WA. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J Infect Dis 1986;154:1033-6.
40. Hedeker D, Gibbons RD. MIXOR: a computer program for mixed-effects ordinal regression analysis. Comput Methods Programs Biomed 1996;49:157-76.
41. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents [review]. J Clin Invest 2001;108:1097-104.
42. Schaad UB. Arthritis in disease due to Neisseria meningitidis [review]. Rev Infect Dis 1980;2:880-8.
43. Likitnukul S, McCracken GH Jr, Nelson JD. Arthritis in children with bacterial meningitis. Am J Dis Child 1986;140:424-7.
44. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr 1981;99:540-5.
45. Vlacha V, Forman EN, Miron D, Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics 1996;97:738-9.
46. Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994;21:1203-6.
47. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002;61:623-5.
48. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.
49. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004;350:896-903.
50. Uziel Y, Pomeranz A, Brik R, Navon P, Mukamel M, Press J, et al. Seasonal variation in systemic onset juvenile rheumatoid arthritis in Israel. J Rheumatol 1999;26:1187-9.
51. Feldman BM, Birdi N, Boone JE, Dent PB, Duffy CM, Ellsworth JE, et al. Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J Pediatr 1996;129:513-8.
52. Burrage M, Robinson A, Borrow R, Andrews N, Southern J, Findlow J, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 2002;70:4946-54.
53. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001;183:160-3.
54. Richmond P, Goldblatt D, Fusco PC, Fusco JD, Heron I, Clark S, et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 1999;18:641-6.
55. Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:106-11.
56. Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004;31:1356-61.
57. Park CL, Frank AL, Sullivan M, Jindal P, Baxter BD. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics 1996;98:196-200.
58. Nicholson A, Lepow IH. Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity. Science 1979;205:298-9.
59. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003;10:780-6.